

RESEARCH

Open Access

Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer

Richard Castillo², Ngoc Pham¹, Sobiya Ansari^{4,6}, Dmitriy Meshkov¹, Sarah Castillo⁴, Min Li⁴, Adenike Olanrewaju⁴, Brian Hobbs³, Edward Castillo^{4,5} and Thomas Guerrero^{1,4,5,7*}

Abstract

Background: A retrospective analysis is performed to determine if pre-treatment [¹⁸F]-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) image derived parameters can predict radiation pneumonitis (RP) clinical symptoms in lung cancer patients.

Methods and Materials: We retrospectively studied 100 non-small cell lung cancer (NSCLC) patients who underwent FDG PET/CT imaging before initiation of radiotherapy (RT). Pneumonitis symptoms were evaluated using the Common Terminology Criteria for Adverse Events version 4.0 (CTCAEv4) from the consensus of 5 clinicians. Using the cumulative distribution of pre-treatment standard uptake values (SUV) within the lungs, the 80th to 95th percentile SUV values (SUV₈₀ to SUV₉₅) were determined. The effect of pre-RT FDG uptake, dose, patient and treatment characteristics on pulmonary toxicity was studied using multiple logistic regression.

Results: The study subjects were treated with 3D conformal RT (n = 23), intensity modulated RT (n = 64), and proton therapy (n = 13). Multiple logistic regression analysis demonstrated that elevated pre-RT lung FDG uptake on staging FDG PET was related to development of RP symptoms after RT. A patient of average age and V₃₀ with SUV₉₅ = 1.5 was an estimated 6.9 times more likely to develop grade ≥ 2 radiation pneumonitis when compared to a patient with SUV₉₅ = 0.5 of the same age and identical V₃₀. Receiver operating characteristic curve analysis showed the area under the curve was 0.78 (95% CI = 0.69 – 0.87). The CT imaging and dosimetry parameters were found to be poor predictors of RP symptoms.

Conclusions: The pretreatment pulmonary FDG uptake, as quantified by the SUV₉₅, predicted symptoms of RP in this study. Elevation in this pre-treatment biomarker identifies a patient group at high risk for post-treatment symptomatic RP.

Keywords: Standard uptake value, PET/CT, Radiation pneumonitis, NSCLC, Thoracic radiotherapy, Imaging biomarker

Introductions

Radiation pneumonitis (RP), an inflammatory reaction within lung tissue secondary to radiation damage [1,2], is a severe and potentially fatal complication of thoracic radiotherapy (RT). Symptoms of RP include dyspnea, non-productive cough, shortness of breath, fever, and changes in pulmonary function. RP-associated mortality has been noted in the treatment of many cancers including breast [3], esophageal [4,5], lung [6,7], and mesothelioma

[8-10]. Furthermore, the mortality rate among non-small cell lung cancer (NSCLC) patients experiencing severe RP symptoms requiring hospitalization approaches 50% [11]. The variability of RP symptoms onset and intensity with respect to patient specific radiation dose, irradiated lung volume, and pulmonary function has made past prognostication efforts futile [12]. Treatment toxicity including RP remains a barrier to radiation dose escalation in lung cancer [13]. Because RP plays such an important role in defining the therapeutic index for lung cancer, clearly there remains a significant need for patient specific prognostication.

* Correspondence: tguerrero@mdanderson.org

¹The University of Texas Health Science Center, Houston, TX, USA

⁴Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Full list of author information is available at the end of the article

Numerous factors such as percentage of lung irradiated [14-16] and chemotherapy type [3,7,17] have been shown to affect occurrence and degree of RP. Another such factor, interstitial pneumonitis (IP) on pretreatment computed tomography (CT) scans, has been shown to predict an increased risk of symptomatic RP [18-20]. Makimoto et al. [18] found that in patients with primary lung cancer, pre-existing lung disease evidenced by pretreatment radiographic changes was associated with a higher incidence of RP (47.1% vs. 5.3%, $p < 0.001$). Another study showed a correlation between severe RP and pretreatment IP foci in the lung periphery on CT, although exclusion of patients with IP from receiving SBRT led to a reduction in the incidence of severe RP from 18.8% to 3.5% ($p = 0.042$) in subsequent cases [20]. Additionally, among 106 patients treated with thoracic RT, pretreatment interstitial changes on CT were associated with a higher incidence of grade ≥ 3 RP (26% versus 3%, $p < 0.001$) [19]. CT scans and x-rays are not the only method to detect pulmonary inflammatory processes. With [^{18}F]-2-fluoro-2-deoxyglucose positron emission tomography (FDG PET) imaging, pulmonary inflammation manifests as enhanced FDG uptake, thereby allowing for the quantitative assessment of pneumonitis [21-23]. Recently, Petit et al. [24] performed a retrospective study of 101 NSCLC patients to evaluate the correlation between symptomatic RP and pre-RT FDG PET/CT evidence of pulmonary inflammation. They report that the 95th percentile of the standard uptake value (SUV_{95}) within the lungs was predictive of RP on multivariate analysis ($p = 0.016$), suggesting that the SUV_{95} can be used to screen for RP risk during thoracic RT treatment planning [24].

In this retrospective study, pre-RT FDG PET/CT image derived factors are analyzed as potential prognostic biomarkers of symptomatic RP in NSCLC patients, testing the findings reported by Petit et al. [24]. We hypothesize that these pre-RT image derived factors identify individuals at high risk for symptomatic RP.

Methods and Materials

Patient population

The study population consisted of 100 non-small cell lung cancer patients who were treated in the Department of Radiation Oncology at the University of Texas M. D. Anderson Cancer Center between July 2004 and May 2012, and who had their staging PET/CT imaging within 90 days prior to the start of radiotherapy. All study subjects had biopsy-proven NSCLC, and their imaging studies are available in the electronic medical records. Patient characteristics were obtained for each study subject including age, sex, disease stage, tumor location, smoking history, tumor histologic type, radiation planning, interval between staging PET and RT, concurrent chemotherapy, and pre-existing lung disease (as assessed by FEV1 and

DLCO parameters). Patient identifiers were removed in accordance with a retrospective study protocol (PA11-0801) approved by the MD Anderson Institutional Review Board. Waiver of informed consent was approved by the Institutional Review Board for this retrospective study protocol.

^{18}F -FDG PET/CT imaging

Patients fasted 6 hours prior to the ^{18}F -FDG PET/CT imaging session and were required to have blood glucose levels < 120 mg/dL. Intravenous injection of 629 (range: 550 – 740) MBq of ^{18}F -FDG occurred 60 (range: 52–110) minutes prior to the image acquisition. The General Electric Discovery ST PET/CT scanner (GE Medical Systems, Waukesha, WI) was used to acquire the ^{18}F -FDG PET/CT images. Patients were instructed to breath normally during the PET emission acquisition. The ^{18}F -FDG PET images included in this study acquired before 2006 were attenuation corrected using a non-contrast mid-inspiratory breath-hold CT, and those after used a respiratory averaged CT [25]. PET/CT images were acquired from mid-thigh to the skull base with arms raised. Standard uptake values (SUV) were calculated from the attenuation corrected ^{18}F -FDG PET emission images using the following equation [26]:

$$\text{Standard Uptake Value} = \frac{{}^{18}\text{F-FDG count rate per mL} \times \text{body weight (gm)}}{\text{decay corrected } {}^{18}\text{F-FDG injected dose (Bq)}} \quad (1)$$

Radiation treatment planning

Treatment planning for megavoltage x-ray cases was performed using the Pinnacle³ version 7.6c or 8.0u treatment-planning system (Philips Medical Systems, Andover, MA). Proton therapy cases were planned using the respiratory averaged CT and the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA). Gross target delineation and margin generation were performed in a consistent manner, as previously reported by our group [27]. Radiation dose was calculated using either free-breathing treatment planning CT data (most cases) or averaged CT data obtained from the treatment planning 4D CT image set [28,29]. All treatment plans and field arrangements were prospectively reviewed in quality assurance meetings in which consensus was obtained according to each patient's clinical circumstances. The radiation dose distributions were all calculated using lung heterogeneity corrections. The mean lung dose (MLD) and the percentage of lung volume irradiated to above 5 Gy or CGE (V_5), 10 Gy or CGE (V_{10}), 20 Gy or CGE (V_{20}), and 30 Gy or CGE (V_{30}) were used as dosimetric parameters to represent the lung volumes irradiated.

For proton cases, all plans were designed for passive scattering delivery. Using a constant relative biological

effectiveness (RBE) of 1.1, proton therapy doses were converted to ^{60}Co Gray Equivalents (CGE).

Clinical Toxicity and Radiation Parameters

Pneumonitis was scored using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4 (CTCAE v4). All patient documents were used in the scoring, including consultation notes, radiographic images, clinic notes, summaries and scanned outside medical records until 6 months after completing radiation. A simple group consensus of 5 clinicians was used for each score. Cases were reviewed until all discrepancies were resolved by unanimous agreement. Clinically symptomatic pneumonitis was defined as grade 2 or higher. All patients with RP scores > 1 had radiographic findings consistent with RP within the radiotherapy treatment field. These findings were evident on follow-up CT imaging and/or PET/CT.

Image analysis

The treatment plan and PET/CT images for each patient were processed and evaluated using custom MATLAB software (v2011a, Mathworks, Inc.). Lung regions of interest (ROIs) were segmented semi-automatically using histogram segmentation of the lung parenchyma and removal of the central airway by connectivity. PET spill-over artifacts (Figure 1) attributable to liver, heart, or tumor activities were manually contoured for exclusion from the segmented lung volume. Attenuation cold-spot artifacts at

the diaphragm surface [30] were also manually removed. The effect of manual editing on the lung ROI and subsequent analysis was assessed according to repeat image segmentation performed by 3 independent secondary reviewers in a subsample of 10 patients (10% of all cases). The primary reader binary lung ROI was used in subsequent analyses.

Pretreatment PET/CT analysis

Using the pretreatment FDG PET images, the SUV of all voxels within the lung ROI were binned into histograms, and the mean SUV (SUV_{mean}), the standard deviation of the SUV (SUV_{SD}), and the maximum SUV (SUV_{max}) were calculated as described in Petit et al. [24]. A cumulative probability distribution was constructed from each histogram (Figure 2) and used to determine the 80th, 90th, and 95th percentiles of the SUV distribution, hereafter designated: SUV_{80} , SUV_{90} , and SUV_{95} , respectively. To determine if pre-treatment CT density could predict RP, the cumulative density parameters mentioned above were also calculated for Hounsfield Unit (HU) of the CT scan: the HU_{mean} , HU_{SD} , HU_{max} , HU_{80} , HU_{90} , and HU_{95} .

Statistical Analysis

Categorical variables (i.e., gender, tumor stage, tumor location, tumor histologic type, radiotherapy modality, chemotherapy status, smoking status, GOLD classification) were summarized using frequency tables; evaluated for association with symptomatic (grade ≥ 2) RP using Pearson's





Figure 1 Lung segmentation and removal of PET spill-over activity artifacts. Semi-automated histogram segmentation and morphological region growing were used to delineate the set of lung voxels on the pre-treatment staging PET/CT studies. PET spill-over activities into the lung ROI were manually contoured for exclusion. *Top row:* lung ROI shown (a) before and (b) after manual correction of cardiac spill-over activity. *Bottom row:* the region of exclusion due to tumor is show in red (c) before and (d) after manual correction.



chi-squared test for marginal homogeneity. Age and the interval between radiotherapy and PET imaging were summarized by median and range; evaluated for association with symptomatic (grade ≥ 2) radiation pneumonitis using Mann–Whitney U tests. Univariate logistic regression analyses were used to predict symptomatic (grade ≥ 2) RP as functions of pre-RT pulmonary and dosimetry characteristics (i.e., SUV, HU, MLD, irradiated volume, FEV1%, DLCO%). Post-hoc application of the sequentially rejective Bonferroni method [31] was used to adjust for multiplicity among the six SUV analyses.

Multiple logistic regression inference used stepwise backward model selection based on Akaike information criterion [32]. Results are provided for the best subset of predictors (SUV_{95} , V_{30} , age). Partial effects were evaluated for significance using two-sided Wald tests. Nagelkerke's coefficient of multiple determination [33] is used to report the proportion reduction in error variation obtained by incorporating the predictors. The resultant receiver operating characteristic (ROC) curve is provided with Delong's 95% confidence interval [34] for the area under the curve (AUC) and Youden's optimal [35] specificity and sensitivity. Additionally, recursive partitioning analysis [36] was used to formulate a binary classification tree based upon both SUV_{95} and V_{30} . Kaplan-Meier curves were used to compare time to radiation pneumonitis symptom development among the observed terciles of SUV_{95} ($SUV_{95} < 0.99$, $0.99 \leq SUV_{95} < 1.2$, $SUV_{95} \geq 1.2$); Cox proportional hazard regression was used to evaluate the rate of RP symptom development as a function of SUV_{95} adjusted for patient and treatment characteristics. Stepwise backward model selection used generalized Akaike information criterion [29]. Results are provided for the best subset of predictors (SUV_{95} , V_{30} , age). Inter-reviewer variability in determination of SUV_{95} was assessed for 3 independent reviewers in a subsample of 10 patients; 95% limits of agreement were estimated using one-way mixed effects ANOVA [37].

The resultant Bland-Altman plot [38] is provided. All tests were two sided with $\alpha = 0.05$ to confer statistical significance. All plots and analyses were performed using the statistical software R (R Development Core Team, <http://www.r-project.org>) version 3.0.

Results

Patient Characteristics and RP Symptoms

An overview of the 100 study subjects and their characteristics is presented in Tables 1 and 2. Of the study participants, 14 (14%) were treated with RT alone while 86 (86%) received concurrent chemo-radiation (chemoRT). The prescription dose range was 36 to 74 Gy (median 66) over 12–37 fractions (median 35). The mean lung dose was between 2.88 and 29.43 Gy (median 17.86 Gy). Consensus CTCAEv4 RP symptom scores were: 10 patients (10%) had no evidence of respiratory symptoms or imaging changes (grade 0), 31 patients (31%) had only radiographic or mild respiratory symptoms without requirement of intervention (grade 1), 27 patients (27%) had post-RT respiratory symptoms affecting the extended activities of daily living (grade 2), 23 (23%) required oxygen (grade 3), 1 (1%) respiratory failure requiring intubation (grade 4) and, 8 (8%) died from respiratory compromise (grade 5). A total of 60% of the patients experienced symptomatic RP.

The patient demographics, stage, tumor location, tumor histology, treatment type and smoking history are reported in Table 1 for the total and symptomatic (CTCAEv4 RP grade ≥ 2). Treatment characteristics and outcomes are listed in Table 2. The data lacked significant evidence to conclude that the presence of symptomatic RT was associated with other clinical factors including tumor stage, histology, location, type of RT, or preexisting lung disease based on FEV1 parameters, as well as any CT-derived imaging parameters.

Table 1 Patient Characteristics

Parameter	Total (%)	Symptomatic ^a N (%)	p-value
No of patients	100 (100)	59 (59)	
Gender			0.65
Male/Female	60(60)/40(40)	35(58.3)/26(65)	
Age			0.011
Symptomatic (IQR)		59.5-73 yrs	
Asymptomatic (IQR)		54-66 yrs	
Stage^b			0.36
I	6 (6)	1 (16.7)	
II	5 (5)	4 (80)	
III	78 (78)	48 (61.5)	
IV	11 (11)	6 (54.5)	
Tumor location^b			0.97
LLL	15 (15)	10 (66.7)	
LUL	25 (25)	15 (60)	
RLL	9 (9)	6 (66.7)	
RML	6 (6)	4 (66.7)	
RUL	45 (45)	24 (53.3)	
Tumor histology^b			0.66
Adenocarcinoma	57 (57)	30 (52.6)	
Neuroendocrine	1 (1)	1 (100)	
Non-small	18 (18)	13 (72.2)	
Squamous	24 (24)	15 (62.5)	
Treatment type^b			0.89
IMRT	64 (64)	35 (54.7)	
Proton	13 (13)	9 (69.2)	
3D Conformal	23 (23)	15 (65.2)	
Chemotherapy status			0.66
Concurrent	86 (86)	52 (60.5)	
RT alone	14 (14)	7 (50)	
Smoking history^b			0.92
Currently	28 (28)	15 (53.6)	
Former	66 (66)	40 (60.6)	
Never	6 (6)	4 (66.7)	
Interval between staging PET/CT and start of RT			0.65
Median (range) in days	18 (3-69)	15 (3-69)	

^aSymptomatic status: CTCAEv4 RP grade ≥ 2 .

^bYates' continuity correction applied.

IQR: Inter-quartile range.

Note: Hypothesis testing for association used the Mann-Whitney *U* test for continuous predictors; Pearson's chi-squared test for marginal homogeneity for categorical predictors.

PreRT SUV_{95} , V_{30} and age predict for radiation pneumonitis

Age was the only non-modifying factor found to be significantly associated with the development of symptomatic RP using the Mann-Whitney *U* hypothesis test. Univariate logistic regression analyses are summarized in

Table 2 Treatment characteristics and outcomes

Treatment dose (Gy or CGE)	
Range (median)	36 – 74 (66)
Mean lung dose (Gy or CGE)	
Range (median)	2.88 – 29.43 (17.86)
^a Radiation pneumonitis symptom score, n (%)	
0	10 (10)
1	31 (31)
2	27 (27)
3	23 (23)
4	1 (1)
5	8 (8)
Pre-RT pulmonary function test, range (median)	
FEV ₁ (%)	30 – 124 (72.5)
DLCO (%)	23 – 125 (64)

^aSymptomatic status: CTCAEv4 RP grade ≥ 2 .

Table 3. Odds of grade ≥ 2 radiation pneumonitis increased with SUV_{mean} , SUV_{SD} , SUV_{80} , SUV_{90} , and SUV_{95} as well as V_{30} . SUV_{95} was the most significant independent predictor of post-radiation lung toxicity ($p < 0.0049$). In addition, significant partial effects were observed for SUV_{95} ($p < 0.0027$), V_{30} ($p < 0.007$), and age ($p < 0.0026$) in the multiple logistic regression analysis provided in Table 4. For a given age and value of V_{30} , each incremental increase in SUV_{95} of size 0.1 was associated with a 1.5-fold increase (95% CI: 1.1 – 1.9, $p < 0.0027$) in the partial odds of symptomatic RP. A patient of average age (64) and V_{30} (23.8) with a value of $SUV_{95} = 1.2$ (1.5) is 1.4 (6.9) times more likely to develop symptomatic RP when compared to a patient presenting with $SUV_{95} = 1$ (0.5) of the same age and identical V_{30} . Additionally, the partial odds of symptomatic RP increased 2.2-fold with each increase in age of 1 year and 1.1-fold with each unit increase in V_{30} , respectively.

Receiver Operating Characteristic (ROC) analysis derived from pre-treatment SUV_{95} , V_{30} , and age to predict symptomatic (grade ≥ 2) radiation pneumonitis is shown in Figure 3. The area under the ROC curve derived from the multiple logistic regression inference was found to be 0.78 (95% CI = 0.69 – 0.87) with Youden's optimal sensitivity = 92% and specificity = 51%. The distribution of symptomatic and asymptomatic is plotted against SUV_{95} and V_{30} in Figure 4. Recursive partition analysis for classification of RP symptoms using pre-treatment SUV_{95} and V_{30} in 3 cohorts is also shown. The optimal partition (assuming identical misclassification costs) derives from classifying patients with pre-treatment $SUV_{95} > 0.949$ or $V_{30} > 27.14$ as symptomatic, patients with $SUV_{95} < 0.949$ and $V_{30} < 27.14$ as asymptomatic. The joint classification tree results in sensitivity = 98% and specificity = 37%.

Table 3 Logistic regression analysis for grade ≥ 2 RP

Predictor	Coefficient	SE	Odds ratio (95% CI)	p-value
SUV _{max}	0.16	0.095	1.2 (0.97, 1.4)	0.10
SUV _{mean}	0.34	0.15	1.4 (1.1, 1.9)	<0.02 ^{a,b}
SUV _{SD} ¹	1.5	0.54	4.4 (1.5, 12.8)	<0.0057 ^{a,b}
SUV ₈₀ ¹	0.31	0.13	1.4 (1.1, 1.7)	<0.013 ^{a,b}
SUV ₉₀ ¹	0.33	0.12	1.4 (1.1, 1.7)	<0.0061 ^{a,b}
SUV ₉₅ ¹	0.33	0.12	1.4 (1.1, 1.7)	<0.0049 ^{a,b}
HU _{max} ²	0.013	0.02	1 (0.97, 1.1)	0.51
HU _{mean} ²	-0.09	0.34	0.91 (0.47, 1.8)	0.79
HU _{sd} ²	-0.18	0.93	0.83 (0.14, 5.1)	0.85
HU ₈₀ ²	-0.07	0.37	0.93 (0.46, 1.9)	0.85
HU ₉₀ ²	-0.10	0.32	0.91 (0.48, 1.7)	0.76
HU ₉₅ ²	-0.10	0.32	0.91 (0.48, 1.7)	0.76
MLD ³	0.88	0.58	2.4 (0.78, 7.5)	0.13
V ₅ ³	0.15	0.53	1.2 (0.41, 3.3)	0.77
V ₁₀ ³	0.58	0.55	1.8 (0.6, 5.3)	0.30
V ₂₀ ³	1.1	0.63	3 (0.87, 10.5)	0.081
V ₃₀ ³	1.2	0.57	3.3 (1.1, 10.3)	0.035
FEV1(%) ²	-0.13	1	0.88 (0.12, 6.6)	0.897
DLCO(%) ²	-1.2	1.1	0.31 (0.034, 2.9)	0.31

¹Scaled by 10.

²Scaled by 0.01.

³Log-transformation applied to improve model fit.

^aSequentially rejective Bonferroni method applied to adjust for multiplicity at the $\alpha = 0.05$ familywise significance level.

^bOdds of grade ≥ 2 radiation pneumonitis increased with SUV_{mean}, SUV_{SD}, SUV₈₀, SUV₉₀, and SUV₉₅.

Note: SE = standard error of the estimated coefficient parameter; CI = confidence interval for the odds ratio; p-values derived from two-sided hypothesis tests using Wald chi-square.

SUV₉₅ Influences Time to Development of Radiation Pneumonitis

Among patients who developed symptomatic RP, the average time from start of RT to symptomatic development was observed to be 3.5 months for patients with SUV₉₅ > 0.99

Table 4 Multiple logistic regression analysis for grade ≥ 2 RP (N = 100)

Predictor	Coefficient	SE	Odds ratio (95% CI)	p-value
Intercept	-6.1	1.7		
SUV ₉₅	0.40	0.13	1.5 (1.1-1.9)	<0.0027
Age ^b	0.79	0.26	2.2 (1.3-3.7)	<0.0026
V ₃₀	0.09	0.034	1.1 (1-1.2)	<0.007

^aScaled by 10.

^bStandardized age was used with origin corresponding to the mean of 64.

Note: SE = standard error of the estimated coefficient parameter; CI = confidence interval for the odds ratio; Stepwise backward model selection based on Akaike information criterion was used; Symptomatic radiation pneumonitis was conditionally independent of tumor location, stage, histology, smoking status, MLD, and RT modality in the presence of SUV₉₅, V₃₀, and age; p-values derived from two-sided hypothesis tests using Wald chi-square; significant partial effects suggest that the odds of symptomatic radiation pneumonitis increased with SUV₉₅, V₃₀, and age; Nagelkerke coefficient of multiple determination R² = 0.32.




Figure 3 Receiver operating characteristics curve for RP symptoms. Receiver Operating Characteristic (ROC) curve (solid) derived from pre-treatment SUV₉₅, V₃₀, and age to predict symptomatic (grade ≥ 2) radiation pneumonitis. The area under the ROC curve derived from the multiple logistic regression inference was found to be 0.78 (95% CI: 0.69 – 0.87) with Youden's optimal sensitivity = 92% and specificity = 51%.

and 4.5 months for patients with SUV₉₅ < 0.99. Kaplan-Meier curves were constructed to compare time to radiation pneumonitis symptoms among subsets of patients within observed terciles of SUV₉₅ (SUV₉₅ < 0.99, 0.99 \leq SUV₉₅ < 1.2, SUV₉₅ \geq 1.2). Figure 5 shows that patients with SUV₉₅ \geq 1.2 developed symptoms at a rate 2.39 (1.19, 4.82) times the rate of patients with SUV₉₅ < 0.99, while patients with 0.99 \leq SUV₉₅ < 1.2 developed symptoms at a rate 2.25 (1.12, 4.52) times greater.

Additionally, multiple Cox proportional hazards regression was used to evaluate the association between SUV₉₅ and time to development of symptomatic RP, adjusted for age and V₃₀ (Table 5). The odds of developing symptomatic RP within a given duration of time increased with SUV₉₅, age, and V₃₀. SUV₉₅ contributed the most significant partial effect (p < 0.002). Given age and V₃₀, each incremental 0.1 increase in SUV₉₅ was associated with a 1.2-fold increase (1.1, 1.3) in the partial hazard rate of RP symptom development.

Inter-reviewer agreement for acquisition of SUV₉₅

Inter-reviewer agreement among three independent reviewers for determination of SUV₉₅ using a representative 10% of all cases (10 subsampled patients) is plotted in Figure 6. Inter-reviewer deviation was within approximately 6% of the reviewer average at the $\alpha = 0.05$ significance level.





Table 5 Cox proportional hazards regression analysis for time to radiation pneumonitis symptoms (N = 100)

Predictor	Coefficient	SE	Hazard ratio (95% CI)	p-value
SUV_{95}^a	0.18	0.057	1.2 (1.1-1.3)	<0.002
Age ^b	0.34	0.14	1.4 (1.1-1.8)	0.013
V_{30}	0.05	0.02	1.1 (1-1.1)	0.011

^aScaled by 10.


^bStandardized age was used with origin corresponding to the mean of 64.

Note: SE = standard error of the estimated coefficient parameter; CI = confidence interval for the hazard ratio; Stepwise backward model selection based on generalized Akaike information criterion was used; symptomatic radiation pneumonitis was conditionally independent of tumor location, stage, histology, smoking status, treatment type, and MLD in the presence of SUV_{95} , V_{30} , and age; p-values derived from two-sided hypothesis tests using Wald chi-square; the rate of symptom development was increased significantly with SUV_{95} , V_{30} , and age.

The observed variation among reviewers reflects the inherent subjectivity associated with the manual intervention to remove PET spill-over activity artifacts (Figure 1) and SUV cold spot artifacts at the lung/diaphragm interface due to respiration. While deviation on the order of 6% is not innocuous given the magnitude of association between the risk of RP and the pre-treatment SUV_{95} , this represents the 95% limit of agreement based upon a subset of 10 patients. Thus we expect on average that inter-reader deviation would be on the order of $\pm 3\%$, which corresponds to only a 0.88 to 1.12-fold change in the odds of symptomatic RP.

Discussion

In this study, we demonstrated the potential of a quantitative image derived prognostic biomarker, the SUV_{95} , for the pre-treatment identification of NSCLC patients at high



risk to develop symptomatic RP. This biomarker provides a quantitative assessment of pre-existing pulmonary inflammation [22,39], which in turn predicts the individual subject's ability to tolerate thoracic radiation without toxicity. This study, which includes a mixture of proton and photon treated lung cancer cases, replicates the finding of Petit et al. [24] who studied a photon-only treated NSCLC cohort. Dehing et al. [40] previously analyzed data from a photon-only treated cohort of 438 patients with NSCLC or SCLC to assess predictive value of patient characteristics and dosimetric parameters associated with dyspnea following thoracic chemo-radiotherapy. Univariate models with V_{20} (mean: 21%, SD: 7.3%) or MLD (mean: 13.5 Gy, SD: 4.5 Gy) both yielded AUC of 0.47. The final multivariate model, which included WHO-performance status, smoking status, forced expiratory volume, age, and MLD, yielded an AUC of 0.62 (95% CI: 0.55-0.69). However, the authors cite that baseline dyspnea scores were not available to rule out the possibility that patients with low FEV1 values already had an elevated dyspnea score prior to treatment. The current study supports the previous findings by Dehing et al. that a combination of patient-related factors and dosimetric parameters, namely the SUV_{95} , V_{30} , and age, is better suited as a prognostic indicator for symptomatic outcomes following thoracic radiotherapy. Pretreatment FDG PET/CT imaging is already routinely obtained for staging of NSCLC [41-43] and has an emerging role in target delineation for radiotherapy treatment planning for NSCLC [44,45]. The SUV_{95} , computed from imaging studies already obtained for staging and treatment planning, can be used to stratify toxicity risk without incurring additional cost.

Notably, the significant association between Hounsfield Unit derived parameters and increase in dyspnea reported by Petit et al. [24] did not hold in the current analysis. The difference may arise due to the difference in CT acquisition methods between studies. Although Petit et al. describe both respiratory gated 4D-CT and low-dose CT with intravenous contrast for each patient, it is not clear which CT image set was utilized to calculate the lung region of interest (ROI) Hounsfield Unit values. In this study, Hounsfield Unit ROI parameters were derived utilizing the radiotherapy treatment planning CT, which was a mix of either free-breathing CT (FB-CT) or 4D-CT.

Other imaging modalities have been utilized to estimate the pretreatment symptomatic RP risk. The relationship between the radiation dose distribution and subsequent RP has been well studied and is summarized nicely by Rodrigues et al. [6]. Single photon emission computed tomography (SPECT) perfusion imaging has been utilized to demonstrate radiation-induced lung toxicity [46,47], showing a nearly linear loss of perfusion with radiation dose. Kocak et al. [12] prospectively tested RP prediction models based on pulmonary perfusion and radiation dose

distributions using models built from one data set and tested on two other data sets. Those models were unable to segregate patients into high and low risk of RP groups in the test data sets. Others have utilized pretreatment ventilation imaging to predict RP in single cohort retrospective studies [48]; however the ROC AUC was small. Hope et al. [49] developed a 3-parameter model (from the tumor superior-inferior relative position, maximum dose, and dose to the hottest 35% of the lung volume), which was tested using a separate data set (RTOG 9311) by Bradley et al. [50] and performed poorly. The STRIPE meta-analysis of pneumonitis after chemoradiotherapy for lung cancer [7] found that concurrent paclitaxel, age, and V_{20} were significant predictive factors with odds ratios of 5.58, 1.38, and 1.07 respectively. Paclitaxel is a radiosensitizer of lung tissue [3,51] that can cause pneumonitis even when used alone [52-54]. The SUV_{95} quantifies pre-existing pulmonary inflammation, the severity of which may reflect the underlying individual propensity toward an inflammatory response.

For lung cancer clinical trials involving thoracic radiation with pulmonary toxicity as an end-point, the SUV_{95} can be utilized to (1) ensure equally balanced arms or (2) exclude those who appear to have a nearly 100% certainty of developing symptomatic pulmonary toxicity. An analysis of a prospective clinical trial conducted by the Radiotherapy Oncology Group (RTOG) indicates higher biologically effective doses of radiotherapy are associated with improved outcomes [55]. However, the recently completed prospective study RTOG 0617 found no advantage as well as increased toxicity in the higher dose arm [13]. Biomarkers such as the SUV_{95} may be used for stratification to enroll only low RP risk study subjects. The SUV_{95} can also be utilized to identify a subgroup at high risk for the development of RP symptoms for clinical trials studying RP-prevention drugs. A cohort with an expected high incidence of RP would power a drug RP prevention trial using fewer study subjects to measure a reduction in RP toxicity events.

Our study was limited by the retrospective nature of this analysis, which could contain inherent biases that we are not aware of despite our best efforts to control for potential confounders. The 3D-CRT patients were treated in an earlier time period, which may have accounted for increased toxicities with less modern imaging and treatment planning techniques. Additionally, the 3D PET images were not acquired with motion correlation [56], thus contributing to spatial blurring and spill-over activity artifacts that required manual intervention processes to exclude from data analysis. Pneumonitis grade was scored using the medical record rather than standardized questionnaires. A prospective study addressing the pulmonary toxicity should include standardized survey such as the St. George Respiratory Questionnaire [57].

Conclusions

In the present study, patients with high FDG uptake prior to treatment were more likely to develop symptomatic RP. Our findings may be used to identify patients at high risk for radiation-induced lung damage so that interventions can be developed and fatal RP avoided.

Abbreviations

RP: Radiation pneumonitis; RT: Radiotherapy; NSCLC: Non-small cell lung cancer; CT: Computed tomography; IP: Interstitial pneumonitis; FDG: ¹⁸F-2-fluoro-deoxyglucose; PET: Positron emission tomography; SUV: Standard uptake value; MLD: Mean lung dose; CGE: ⁶⁰Co Gray Equivalents; CTCAE v4: National Cancer Institute Common Terminology Criteria for Adverse Events version 4; ROI: Region of interest; HU: Hounsfield Unit; ROC: Receiver operating characteristic; AUC: Area under the curve; RTOG: Radiotherapy oncology group.

Competing interests

The authors have no commercial or financial interests related to this study to disclose.

Authors' contribution

RC contributed to study conception and design, data analysis, and drafting of the manuscript. NP, SA, and DM contributed to data analysis and drafting of the manuscript. SC and AO contributed to data acquisition processes and data analysis. ML and EC contributed to the development of data analysis infrastructure, with further contribution to data analysis processes. BH performed statistical testing and contributed to drafting of the manuscript. TG formulated study conception and design, and contributed to drafting of the manuscript. All authors provided final approval of the manuscript version to be published.

Acknowledgments

We extend our warmest gratitude to the thoracic radiation oncology faculty, thoracic surgeons, and gastrointestinal medical oncologists at M. D. Anderson whose patients comprised this study. This work was partially funded by the National Institutes of Health through a National Cancer Institute Grant R21CA141833 and through an NIH Director's New Innovator Award DP2OD007044. RC was partially supported by an NIH Research Scientist Development Award K01CA181292.

Author details

¹The University of Texas Health Science Center, Houston, TX, USA. ²Divisions of Diagnostic Imaging, Houston, TX, USA. ³Quantitative Sciences, Houston, TX, USA. ⁴Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁵Department of Computational and Applied Mathematics, Rice University, Houston, TX, USA. ⁶Baylor College of Medicine, Houston, TX, USA. ⁷Department of Radiation Oncology, Unit 97, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Received: 7 October 2013 Accepted: 2 March 2014

Published: 13 March 2014

References

- Ghafoori P, Marks LB, Vujaskovic Z, Kelsey CR: **Radiation-induced lung injury. Assessment, management, and prevention.** *Oncology (Williston Park)* 2008, **22**(1):37–47. discussion 52–3.
- Roberts CM, Foulcher E, Zaunders JJ, Bryant DH, Freund J, Cairns D, Penny R, Morgan GW, Breit SN: **Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction.** *Ann Intern Med* 1993, **118**(9):696–700.
- Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler R, Roche M, Powell SN: **Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel.** *J Natl Cancer Inst* 2001, **93**(23):1806–11.
- Hart J, McCurdy MR, Ezhil M, Wei W, Khan M, Luo D, Munden R, Johnson V, Guerrero T: **Radiation pneumonitis: Correlation of Toxicity with the Pulmonary Metabolic Radiation Response.** *Int J Radiat Oncol Biol Phys* 2008, **71**(4):967–971.
- McCurdy M, Wazni M, Martinez J, McAleer M, Guerrero T: **Exhaled nitric oxide predicts radiation pneumonitis in esophageal and lung cancer patients receiving thoracic radiation.** *Radiotherapy and Oncology* 2011, **101**:443–448.
- Rodrigues G, Lock M, D'Souza D, Yu E, Van Dyk J: **Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer—a systematic review.** *Radiotherapy and Oncology* 2004, **71**(2):127–138.
- Palma D, Senan S, Tsujino K, Barriger R, Rengan R, Moreno M, Bradley J, Kim T, Ramella S, Marks L, de Petris L, Stitt L, Rodrigues G: **Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis.** *Int. J. Radiation Oncology Biol. Phys.* 2013, **85**(2):444–450.
- Allen AM, Czerminska M, Janne PA, Sugarbaker DJ, Bueno R, Harris JR, Court L, Baldini EH: **Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.** *Int J Radiat Oncol Biol Phys* 2006, **65**(3):640–5.
- Kristensen CA, Notttrup TJ, Berthelsen AK, Kjaer-Kristoffersen F, Ravn J, Sorensen JB, Engelholm SA: **Pulmonary toxicity following IMRT after extrapleural pneumectomy for malignant pleural mesothelioma.** *Radiother Oncol* 2009, **92**(1):96–9.
- Rice DC, Smythe WR, Liao Z, Guerrero T, Chang JY, McAleer MF, Jeter MD, Correa A, Vaporciyan AA, Liu HH, Komaki R, Forster KM, Stevens CW: **Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.** *Int J Radiat Oncol Biol Phys* 2007, **69**(2):350–7.
- Wang JY, Chen KY, Wang JT, Chen JH, Lin JW, Wang HC, Lee LN, Yang PC: **Outcome and prognostic factors for patients with non-small-cell lung cancer and severe radiation pneumonitis.** *International Journal of Radiation Oncology, Biology, Physics.* 2002, **54**(3):735–41.
- Kocak Z, Borst GR, Zeng J, Zhou S, Hollis DR, Zhang J, Evans ES, Folz RJ, Wong T, Kahn D, Belderbos JS, Lebesque JV, Marks LB: **Prospective assessment of dosimetric/physiologic-based models for predicting radiation pneumonitis.** *Int J Radiat Oncol Biol Phys* 2007, **67**(1):178–186.
- Bradley J, Paulus R, Komaki R, Masters G, Forster K, Schild S, Bogart J, Garces Y, Narayan S, Kavadi V, Nedzi L, Michalski J, Johnson D, MacRae R, Curran W, Choy H: **A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.** *J Clin Oncol* 2013, **31**(supp):7501.
- Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA: **Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC).** *Int J Radiat Oncol Biol Phys* 1999, **45**(2):323–9.
- Claude L, Perol D, Ginestet C, Falchero L, Arpin D, Vincent M, Martel I, Hominal S, Cordier JF, Carrie C: **A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.** *Radiother Oncol* 2004, **71**(2):175–81.
- Rancati T, Ceresoli GL, Gagliardi G, Schipani S, Cattaneo GM: **Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study.** *Radiother Oncol* 2003, **67**(3):275–83.
- Guerrero T, Martinez J, McCurdy M, Wolski M, McAleer M: **Elevation in exhaled nitric oxide predicts for radiation pneumonitis.** *Int. J. Radiation Oncology Biol. Phys.* 2012, **82**(2):981–988.
- Makimoto T, Tsuchiya S, Hayakawa K, Saitoh R, Mori M: **Risk factors for severe radiation pneumonitis in lung cancer.** *Japanese Journal of Clinical Oncology.* 1999, **29**(4):192–7.
- Sanuki N, Ono A, Komatsu E, Kamei N, Akamine S, Yamazaki T, Mizunoe S, Maeda T: **Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy.** *J. Radiat. Res.* 2012, **53**:110–116.
- Yamashita H, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, Ohtomo K, Nakagawa K: **Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy.** *Oncology: Radiation;* 2010. **5**(32).
- Jones HA, Clark RJ, Rhodes CG, Schofield JB, Krausz T, Haslett C: **In vivo measurement of neutrophil activity in experimental lung inflammation.** *Am J Respir Crit Care Med* 1994, **149**(6):1635–1639.
- Chen DL, Rosenbluth DB, Mintun MA, Schuster DP: **FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin.** *J Appl Physiol* 2006, **100**(5):1602–1609.

23. Chen DL, Ferkol TW, Mintun MA, Pittman JE, Rosenbluth DB, Schuster DP: **Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography.** *Am J Respir Crit Care Med* 2006, **173**(12):1363–1369.
24. Petit S, van Elmpot W, Oberije C, Vegt E, Dingemans A, Lambin P, Dekker A, de Ruyscher D: **Fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients.** *J Radiation Oncology Biol Phys* 2011, **81**(3):698–705.
25. Pan T, Mawlawi O, Nehme SA, Erdi YE, Luo D, Liu HH, Castillo R, Mohan R, Liao Z, Macapinlac HA: **Attenuation Correction of PET Images with Respiration-Averaged CT Images in PET/CT.** *J Nucl Med* 2005, **46**(9):1481–1487.
26. Strauss LG, Conti PS: **The applications of PET in clinical oncology.** *J Nucl Med* 1991, **32**(4):623–648.
27. Liao Z, Liu H, Komaki R: **Target delineation for esophageal cancer.** *Journal of Women's Imaging* 2003, **5**(4):177–186.
28. Vedam SS, Keall PJ, Kini VR, Mostafavi H, Shukla HP, Mohan R: **Acquiring a four-dimensional computed tomography dataset using an external respiratory signal.** *Phys Med Biol* 2003, **48**(1):45–62.
29. Pan T, Lee TY, Rietzel E, Chen GT: **4D-CT imaging of a volume influenced by respiratory motion on multi-slice CT.** *Med Phys* 2004, **31**(2):333–40.
30. Osman MM, Cohade C, Nakamoto Y, Wahl RL: **Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT.** *European journal of nuclear medicine and molecular imaging* 2003, **30**(4):603–606.
31. Proschan MWM: **Practical guidelines for multiplicity adjustment in clinical trials.** *Controlled Clinical Trials*. 2000, **21**:527–539.
32. Akaike H: **A new look at the statistical model identification.** *IEEE T Automat Contr* 1974, **19**(6):716–723.
33. Nagelkerke NJD: **A note on a general definition of the co efficient of determination.** *Biometrika* 1991, **78**:691–692.
34. DeLong ER, DeLong DM, Clarke-Pearson DL: **Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.** *Biometrics* 1988, **44**(3):837–45.
35. Youden WJ: **Index for rating diagnostic tests.** *Cancer* 1950, **3**(1):32–35.
36. Breiman L, Friedman JH, Olshen RA, Stone CJ: *Classification and regression trees*. Monterey, Calif. U.S.A.: Wadsworth, Inc.; 1984.
37. McCulloch C, Searle S, Neuhaus J, Generalized L, Models M, 2nd ed: *Hoboken*. NJ: Wiley; 2008.
38. Bland JM, Altman DG: **Statistical methods for assessing agreement between two methods of clinical measurement.** *Lancet* 1986, **1**(8476):307–10.
39. de Prost N, Tucci MR, Melo MFV: **Assessment of Lung Inflammation With 18 F-FDG PET During Acute Lung Injury.** *American Journal of Roentgenology* 2010, **195**(2):292–300.
40. Dehing-Oberije C, De Ruyscher D, van Baardwijk A, Yu S, Rao B, Lambin P: **The importance of patient characteristics for the prediction of radiation-induced lung toxicity.** *Radiotherapy and Oncology* 2009, **91**:421–426.
41. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AKP, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong F-M, Kris MG, Krug LM, Le Q-T, Lennes IT, Martins R, Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ: **Non-small cell lung cancer.** *Journal of the National Comprehensive Cancer Network*. *JNCCN* 2010, **8**(7):740–801.
42. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, Ravn J, Clementsen P, Høgholm A, Larsen K, Rasmussen T, Keiding S, Dirksen A, Gerke O, Skov B, Steffensen I, Hansen H, Vilman P, Jacobsen G, Backer V, Maltbaek N, Pedersen J, Madsen H, Nielsen H, Højgaard L: **Preoperative Staging of Lung Cancer with Combined PET-CT.** *The New England journal of medicine* 2009, **361**(1):32–39.
43. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, Detterbeck F: **Noninvasive Staging of Non-small Cell Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition).** *Chest* 2007, **132**(3_suppl):178S–201S.
44. Mac Manus MP, Hicks RJ: **The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer.** *Seminars in nuclear medicine* 2012, **42**(5):308–319.
45. Holloway CL, Robinson D, Murray B, Amanie J, Butts C, Smylie M, Chu K, McEwan AJ, Halperin R, Roa WH: **Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer.** *Radiother Oncol* 2004, **73**(3):285–7.
46. Marks LB, Munley MT, Spencer DP, Sherouse GW, Bentel GC, Hoppenworth J, Chew M, Jaszczak RJ, Coleman RE, Prosnitz LR: **Quantification of radiation-induced regional lung injury with perfusion imaging.** *Int J Radiat Oncol Biol Phys* 1997, **38**(2):399–409.
47. Marks LB, Spencer DP, Bentel GC, Ray SK, Sherouse GW, Sontag MR, Coleman RE, Jaszczak RJ, Turkington TG, Tapson V: **The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation.** *Int J Radiat Oncol Biol Phys* 1993, **26**(4):659–68.
48. Vinogradskiy Y, Castillo R, Castillo E, Tucker S, Zhongxing L, Guerrero T, Martel M: **Using 4DCT-Based Ventilation Imaging to Correlate Lung Dose and Function with Clinical Outcomes.** *J Radiat Oncol Biol Phys* 2013. in press.
49. Hope AJ, Lindsay PE, El Naqa I, Alaly JR, Vicic M, Bradley JD, Deasy JO: **Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters.** *Int J Radiat Oncol Biol Phys* 2006, **65**(1):112–124.
50. Bradley JD, Hope A, Naqa IE, Apte A, Lindsay PE, Bosch W, Matthews J, Sause W, Graham MV, Deasy JO: **A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data.** *Int J Radiat Oncol Biol Phys* 2007, **69**:984–995.
51. McCurdy M, McAleer MF, Wei W, Ezhil M, Johnson V, Khan M, Baker J, Luo D, Ajani J, Guerrero T: **Induction and Concurrent Taxanes Enhance both the Pulmonary Metabolic Radiation Response and the Radiation Pneumonitis Response in Patients with Esophagus Cancer.** *Int J Radiat Oncol Biol Phys* 2010, **76**(3):816–823.
52. Khan A, McNally D, Tutschka PJ, Bilgrami S: **Paclitaxel-induced acute bilateral pneumonitis.** *Ann Pharmacother* 1997, **31**(12):1471–1474.
53. Wong P, Leung AN, Berry GJ, Atkins KA, Montoya JG, Ruoss SJ, Stockdale FE: **Paclitaxel-induced hypersensitivity pneumonitis: Radiographic and CT findings.** *Am J Roentgenol* 2001, **176**(3):718–720.
54. Schweitzer VG, Juillard GJF, Bajada CL, Parker RG: **Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel.** *Cancer* 1995, **76**(6):1069–1072.
55. Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, Albain K, Sause WT, Curran WJ: **Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non-Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology Group.** *International Journal of Radiation Oncology*Biophysics* 2012, **82**(1):425–434.
56. Didierlaurent D, Ribes S, Caselles O, Jaudet C, Cazalet J-M, Batatia H, Courbon F: **A new respiratory gating device to improve 4D PET/CT.** *Medical Physics* 2013, **40**(3):32501–1–32501–9.
57. Barr JT, Schumacher GE, Freeman S, LeMoine M, Bakst AW, Jones PW: **American translation, modification, and validation of the St. George's Respiratory Questionnaire.** *Clin Ther* 2000, **22**(9):1121–1145.

doi:10.1186/1748-717X-9-74

Cite this article as: Castillo et al.: Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer. *Radiation Oncology* 2014 **9**:74.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

